Fig. 2: Inferred mutational signature analyses assessed by SigMA.
From: Genomic characterization of tumor mutational burden-high breast carcinomas
a Bar chart demonstrating the distribution of inferred dominant signatures in TMB-high BCs (n = 515; signatures were not available for 12 tumors). b Pie charts summarizing mutational signatures according to receptor status. Unavailable signatures are incorporated in the other category. c Box plots depicting the range of TMB values among different signatures with ≥2 tumor samples. Asterisks denote differences of statistical significance: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Horizontal line in box plots denotes median value. d Representative TMB-high BCs with a dominant MSI signature, showing loss of mismatch repair proteins at the protein level by immunohistochemistry, alongside corresponding H&E-stained photomicrographs. Each row represents one tumor. Rows 1 and 2: Loss of MLH1 and PMS2. Row 3: Loss of PMS2. Scale bars, 100 μm. e Box plot (left panel) depicting the range of TMB values in tumors with positive (SP142: ≥ 1%; SP263: CPS ≥ 10) and negative PD-L1 expression by immunohistochemistry (unpaired t-test). Mean value is demonstrated, and the quartile calculation is exclusive of the median. Representative PD-L1 positive and negative cases with corresponding H&E-stained photomicrographs (right panel). Scale bars, 100 μm.
